The short answer
Selank's most specifically characterised activity is inhibition of enkephalin-degrading enzymes. Rather than acting at opioid receptors itself, it slows the breakdown of endogenous enkephalins (particularly leu-enkephalin) so the body's own signalling persists longer. This was measured directly on plasma enkephalinase activity.
Key facts
- Target
- Enkephalin-degrading enzymes
- Effect
- Extended endogenous enkephalin half-life
- Enkephalin most cited
- Leu-enkephalin
- Not
- An opioid receptor ligand
- Measured in
- Plasma enkephalinase activity
- Key references
- PMID 11550013, PMID 12432865
What enkephalins are
Enkephalins are short endogenous opioid peptides, met-enkephalin and leu-enkephalin, each five residues,produced from proenkephalin and acting at delta and mu opioid receptors. They are part of the body's own opioid signalling system, and like most signalling peptides they are cleared rapidly by specific peptidases collectively referred to as enkephalinases.
The difference between agonism and degradation inhibition
This distinction is the whole point and it is routinely muddled. An opioid agonist binds the receptor and activates it directly, at whatever concentration is administered, wherever the drug reaches. A degradation inhibitor does not touch the receptor. It allows the endogenous ligand already being released to persist longer, which means the effect is bounded by the body's own release patterns and occurs only where enkephalins are actually being produced.
Research material referenced
Selank 10mg, third-party HPLC tested
What was measured
Work published in the Bulletin of Experimental Biology and Medicine in 2001 reported an inhibitory effect of Selank on enkephalin-degrading enzymes, proposed as a mechanism for its observed activity. A 2002 study in the same journal examined effects on behavioural measures alongside plasma enkephalin-degrading enzyme activity, linking the biochemical observation to a behavioural one.
Why this mechanism is interesting pharmacologically
Modulating a system by slowing clearance of its endogenous ligand is a different intervention from supplying an exogenous agonist. The effect is self-limiting in a way direct agonism is not, because it depends on there being endogenous ligand to preserve. The same logic underlies DPP-4 inhibitors in the incretin field, which prolong native GLP-1 rather than supplying an analogue, and the comparison is instructive, because that class produces smaller effects than the receptor agonists.
What this does not establish
Enzyme inhibition measured in plasma is a biochemical observation. It does not by itself establish a functional consequence in an organism, and the interventional work here is preclinical. The mechanism is well described; what it produces in humans rests on a clinical literature that is largely Russian-language and difficult to assess independently.
Frequently asked questions
Does Selank act on opioid receptors?
Reported work describes inhibition of enkephalin-degrading enzymes rather than direct receptor binding. It preserves the body's own enkephalins instead of supplying an agonist.
What is an enkephalinase?
A collective term for peptidases that break down enkephalins, clearing them from circulation and from synaptic space.
Is this the same as how DPP-4 inhibitors work?
The logic is analogous (prolong an endogenous peptide rather than supply an analogue) though the peptides and enzymes involved are entirely different.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedZozulya AA et al., Inhibitory effect of Selank on enkephalin-degrading enzymes. Bull Exp Biol Med 2001 (PMID 11550013)pubmed.ncbi.nlm.nih.gov
- PubMedSokolov OY et al., Effects of Selank on behavioural reactions and plasma enkephalin-degrading enzymes. Bull Exp Biol Med 2002 (PMID 12432865)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More Selank (Tuftsin Analogue) articles
- Selank and GABAergic SignallingSelank has been reported to affect GABA-A receptor expression without binding the receptor directly - a different mechanism from benzodiazepines.
- Selank Storage, Stability and ReconstitutionSelank has no cysteine and no methionine, so the two usual degradation routes do not apply. What that changes about handling, and what it does not.
- Selank in the Published LiteratureAbout 135 indexed PubMed records, against 690 for its parent peptide tuftsin. How the mechanistic and clinical literatures split, and how to read them.
- What Is Selank? Sequence, Origin and Enkephalin MechanismSelank is a synthetic heptapeptide built from tuftsin with a Pro-Gly-Pro extension. Structure, enkephalin mechanism, regulatory status and the evidence base.